Commit Biologics is a preclinical company developing a new class of therapeutics based on its Bispecific Complement Engager (BiCE) platform to treat autoimmune diseases and cancer.
The company is focused on advancing BiCE, designed to activate the complement system and induce the highly selective killing of cells of interest.
Speaking to the In Vivo podcast, Wandahl Pederson explained that “the unique thing about Commit’s technology is of course the BiCE technology. The B molecules have a unique ability to engage the C1Q, which is the first protein in the [classical] complement cascade.”
Although the company is yet to have any candidates in the clinic, its next steps will involve generating proof-of-concept data over the next year and selecting a candidate with the greatest potential for pipeline development.
“It’s critical for us that we identify the right asset, the most promising one, the one that differentiates the most. So, we allow ourselves some time to think about that before actually selecting the final candidates that we want to push forward,” said Pederson.
The biotech has secured a cash runway leading to an estimated mid-2027. After launching in May 2024 with €16m in seed funding from Bioqube Ventures and Novo Holdings, Commit secured a €5.5m seed financing extension in January 2025 from Belgian investment company Korys, bringing its total funding to €21.5m.
In Vivo spoke to Wandahl Pederson about Commit Biologics’ ambitious attitude as it continues to develop its BiCE technology and search for collaborations both academically and professionally.
Timestamps:
Overview of the complement system and its role in the immune system – 02:50
BiCE technology - 05:22
New antibody development strategies – 07:50
Regulatory and pipeline strategies – 10:01
Seed funding and future opportunities - 14:32
Career history -17:15
Challenges facing the company and the industry - 19:00
